FHL2 and Graves disease: In Graves’ disease patients, an aberrant hypermethylation was observed for TRIM59, an aberrant hypomethylation for FHL2. In contrast, ELOVL2 and C1orf132 showed unchanged prediction accuracy in all disease groups.